Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Once melanomas have progressed with acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major challenge. We therefore examined the therapy phase before acquired resistance had developed and discovered the melanoma survival oncogene MIT...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cancer cell Ročník 29; číslo 3; s. 270
Hlavní autori:	Smith, Michael P, Brunton, Holly, Rowling, Emily J, Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L, Girotti, Maria R, Marais, Richard, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Flaherty, Keith T, Cooper, Zachary A, Wargo, Jennifer A, Wellbrock, Claudia
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 14.03.2016
Predmet:	Cell Line, Tumor Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Drug Tolerance - genetics GTP Phosphohydrolases - genetics HIV Protease Inhibitors - pharmacology Humans Melanoma - drug therapy Melanoma - genetics Membrane Proteins - genetics Mitogen-Activated Protein Kinases - metabolism Mutation - drug effects Mutation - genetics Nelfinavir - pharmacology Paired Box Transcription Factors - genetics PAX3 Transcription Factor Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - genetics Up-Regulation - drug effects Up-Regulation - genetics
ISSN:	1878-3686, 1878-3686
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!